DK1218352T3 - Benzimidazolonderivater med affinitet for både serotonin- og dopamin-receptorer - Google Patents

Benzimidazolonderivater med affinitet for både serotonin- og dopamin-receptorer

Info

Publication number
DK1218352T3
DK1218352T3 DK00965975T DK00965975T DK1218352T3 DK 1218352 T3 DK1218352 T3 DK 1218352T3 DK 00965975 T DK00965975 T DK 00965975T DK 00965975 T DK00965975 T DK 00965975T DK 1218352 T3 DK1218352 T3 DK 1218352T3
Authority
DK
Denmark
Prior art keywords
serotonin
affinity
dopamine receptors
benzimidazolone derivatives
benzimidazolone
Prior art date
Application number
DK00965975T
Other languages
Danish (da)
English (en)
Inventor
Enzo Cereda
Maura Bignotti
Giovanni Battista Schiavi
Original Assignee
Boehringer Ingelheim Italia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Italia filed Critical Boehringer Ingelheim Italia
Application granted granted Critical
Publication of DK1218352T3 publication Critical patent/DK1218352T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK00965975T 1999-09-22 2000-09-12 Benzimidazolonderivater med affinitet for både serotonin- og dopamin-receptorer DK1218352T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001964A IT1313625B1 (it) 1999-09-22 1999-09-22 Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
PCT/EP2000/008891 WO2001021593A1 (fr) 1999-09-22 2000-09-12 Nouveaux derives de benzimidazolone possedant une affinite mixte envers les recepteurs de serotonine et de dopamine

Publications (1)

Publication Number Publication Date
DK1218352T3 true DK1218352T3 (da) 2004-06-28

Family

ID=11383635

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00965975T DK1218352T3 (da) 1999-09-22 2000-09-12 Benzimidazolonderivater med affinitet for både serotonin- og dopamin-receptorer

Country Status (16)

Country Link
US (1) US6281218B1 (fr)
EP (1) EP1218352B1 (fr)
JP (2) JP4989002B2 (fr)
AR (1) AR025739A1 (fr)
AT (1) ATE266644T1 (fr)
AU (1) AU7653700A (fr)
CA (1) CA2381819C (fr)
CO (1) CO5210864A1 (fr)
DE (1) DE60010732T2 (fr)
DK (1) DK1218352T3 (fr)
ES (1) ES2220541T3 (fr)
IT (1) IT1313625B1 (fr)
MX (1) MXPA02001986A (fr)
PE (1) PE20010600A1 (fr)
PT (1) PT1218352E (fr)
WO (1) WO2001021593A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US7033345B2 (en) * 2002-05-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Deflectable microimplant delivery system
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050215589A1 (en) * 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
JP2007504220A (ja) * 2003-09-03 2007-03-01 ガラパゴス・エヌブイ イミダゾ［１，５−ａ］ピリジン又はイミダゾ［１，５−ａ］ピペリジン誘導体および５ＨＴ２Ａ受容体関連障害に対する薬剤の製造のためのその使用
TW200533348A (en) * 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
JP2007533686A (ja) * 2004-04-22 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 性的障害ｉｉ治療用の新規医薬組成物
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
EP1789048A1 (fr) * 2004-09-03 2007-05-30 Boehringer Ingelheim International GmbH Methode de traitement du trouble de l'hyperactivite avec deficit de l'attention
JP5042028B2 (ja) * 2004-11-05 2012-10-03 セラヴァンス， インコーポレーテッド キノリノン−カルボキサミド化合物
ES2332808T3 (es) * 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
US7419989B2 (en) * 2004-12-22 2008-09-02 Theravance, Inc. Indazole-carboxamide compounds
BRPI0608392A2 (pt) * 2005-03-02 2009-12-29 Theravance Inc compostos de quinolinona como agonistas do receptor 5-ht4
EP1858515A2 (fr) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
WO2006096439A2 (fr) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2006096435A1 (fr) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Compositions pharmaceutiques utiles dans le traitement et/ou la prevention de la depression
CA2608249A1 (fr) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Methode de traitement de la toxicomanie
EP1888071A1 (fr) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Procede pour le traitement de dysfonctionnements sexuels d origine medicamenteuse
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
US7317022B2 (en) * 2005-06-07 2008-01-08 Theravance, Inc. Benzoimidazolone-carboxamide compounds as 5-HT4 receptors agonists
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
WO2007048803A1 (fr) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
MY143574A (en) * 2005-11-22 2011-05-31 Theravance Inc Carbamate compounds as 5-ht4 receptor agonists
CA2642101A1 (fr) * 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Derives de benzimidazolone pour le traitement de l'incontinence urinaire
JP2009536176A (ja) * 2006-05-09 2009-10-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 閉経後の性的欲求障害の治療のためのフリバンセリンの使用
US20090312242A1 (en) * 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (fr) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Utilisation de flibansérine pour le traitement de troubles sexuels chez les femmes
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AR062320A1 (es) * 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CN104721168A (zh) * 2006-08-25 2015-06-24 贝林格尔·英格海姆国际有限公司 控制释放系统及其制造方法
WO2008061968A1 (fr) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh Dérivés de benzimidazolone utiles dans le traitement de l'hypertension artérielle pulmonaire
JP2010513390A (ja) * 2006-12-20 2010-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 混合セロトニン受容体親和性を有する硫酸化ベンズイミダゾロン誘導体
US8304601B2 (en) * 2007-01-23 2012-11-06 Keiko Fujikawa Mouse model for eye disease
UY31335A1 (es) * 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
WO2009092720A1 (fr) * 2008-01-24 2009-07-30 Neurosearch A/S Dérivés de 4-phényl-pipérazin-1-yl-alkyl-benzoimidazol-2-one et leur utilisation en tant qu'inhibiteurs de la réabsorption des neurotransmetteurs monoamines
CA2686480A1 (fr) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh Nouveaux sels
BRPI1003506B1 (pt) 2010-09-24 2019-12-03 Ache Int Bvi Ltd composto alquil-piperazino-fenil-4(3h)quinazolinonas e uso do composto alquil-piperazino-fenil-4(3h)quinazolinonas associado aos receptores serotoninérgicos 5-ht1a e 5-ht2a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.

Also Published As

Publication number Publication date
US6281218B1 (en) 2001-08-28
EP1218352A1 (fr) 2002-07-03
CA2381819A1 (fr) 2001-03-29
ATE266644T1 (de) 2004-05-15
DE60010732T2 (de) 2005-05-25
CA2381819C (fr) 2007-03-13
ES2220541T3 (es) 2004-12-16
CO5210864A1 (es) 2002-10-30
DE60010732D1 (de) 2004-06-17
IT1313625B1 (it) 2002-09-09
JP2003509496A (ja) 2003-03-11
EP1218352B1 (fr) 2004-05-12
ITMI991964A1 (it) 2001-03-22
JP2012067105A (ja) 2012-04-05
JP4989002B2 (ja) 2012-08-01
AR025739A1 (es) 2002-12-11
ITMI991964A0 (it) 1999-09-22
PT1218352E (pt) 2004-09-30
WO2001021593A1 (fr) 2001-03-29
PE20010600A1 (es) 2001-06-04
MXPA02001986A (es) 2002-10-31
AU7653700A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
DK1218352T3 (da) Benzimidazolonderivater med affinitet for både serotonin- og dopamin-receptorer
NO20035359D0 (no) Nye indolderivater med 5-HT6-reseptoraffinitet
EE200100403A (et) Indooli derivaadid ja nende kasutamine MCP-1 antagonistidena
DK1664036T3 (da) Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning
NO20013444L (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
IS5812A (is) 2-setin-1-píperidýl bensimídasól efnasambönd sem ORL1-viðtaka gerandefni
DE69928945D1 (de) 4,4-biarylpiperidinederivate mit opioid-receptor-wirkung
EE200300244A (et) 3-aroüülindooli derivaadid ja nende kasutamine CB2-retseptorite agonistidena
PT1189916E (pt) N-pirazole agonistas do receptor a2a
ATE266023T1 (de) Amid-derivate
NO20052909D0 (no) Tetracyclic 3-substituted indoles having serotonin receptor affinity.
EE9600095A (et) Indooli derivaadid kui 5-HT agonistid
NO20026168D0 (no) 3-azabicyklo(3.1.0)heksan derivater med opioid reseptor affinitet
EE200200135A (et) D4 antagonistidena toimivad tienoisoksasolüül- jatienüülpürrasolüülfenoksü-asendatud propüülderivaadid
DK1189583T3 (da) Indolderivater
AU2002223528A1 (en) New n, n'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
IS6434A (is) Nýjar indól afleiður
NO20020306L (no) Indolderivater
NO976157L (no) Kondenserte tiazolderivater med 5-HT-reseptor-affinitet
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer
FI971854A (fi) Substituoituja tetrasyklisiä atsepiinijohdannaisia, joilla on 5-HT2-reseptoriaffiniteetti
DK1068198T3 (da) 5-Heteroarylsubstituerede indoler
NO20013978D0 (no) Dopamin D1 reseptor agonist forbindelser
PT1207159E (pt) Derivados aroma-heterociclicos como antagonistas de receptores da dopamina d4